NCT01694355

Brief Summary

It is well known that postmenopausal women are at risk for osteoporosis. The study hypothesis is that vitamin D deficiency (≤17.5nmol/L) is frequently associated with osteomalacia and will cause low BMD estimation in DXA scan due to insufficient bone mineralization. We assume that among these postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD. According to the results, bisphosphonates therapy may be an unnecessary treatment. The objective of this study is to evaluate the impact of severe vitamin D deficiency and its correction on Bone Mineral Density (BMD) in postmenopausal women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Oct 2012

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 24, 2012

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 27, 2012

Completed
4 days until next milestone

Study Start

First participant enrolled

October 1, 2012

Completed
6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2018

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2018

Completed
Last Updated

April 5, 2019

Status Verified

April 1, 2019

Enrollment Period

6 years

First QC Date

September 24, 2012

Last Update Submit

April 3, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in BMD (Z score) following 10 months of vitamin D supplementation

    Will be measured at 3 time points (repeated measures):at baseline visit, after 3-4 months and after 10 months of treatment

    10-14 months

Secondary Outcomes (1)

  • To examine the effect of increasing vitamin D levels on other objective parameters such as PTH, calcium, phosphorus and other subjective parameters such as muscle weakness, according to comparison between baseline visit and end of study visit.

    10-14 months

Study Arms (1)

Vitamin D treatment

EXPERIMENTAL

We assume that among postmenopausal women, Vitamin D treatment will improve bone mineralization and will cause a rapid increase in BMD.

Drug: Vitamin D

Interventions

Vitamin D treatment

Eligibility Criteria

Age55 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Signed Informed Consent.
  • Female age 55-70
  • At least 2 years past menopause
  • (OH)D≤ 17.5nmol/L (≤7 ng/ml)

You may not qualify if:

  • \. Vitamin D levels \> 30nmol/L in the past 2 years 2. Creatinine \> 1.2%mg 3. Calcium ≥ 10.2mg/dl 4. Current or previous vitamin D treatment over 2 weeks 5. Previous vitamin D treatment over 2 months in the past 2 years 6. BMI\>35 or BMI\<20 7. Menopause before age 45 8. Type 1 diabetes 9. Concomitant disease:
  • Mal-absorptive diseases (Cystic Fibrosis, Crohn's, gastric bypass surgery, celiac disease)
  • Rheumatoid arthritis
  • Nephrotic syndrome
  • Chronic renal failure
  • Primary hyperparathyroidism
  • Hyperthyroidism
  • Malignancies excluding skin cancers (within the last 5 years)
  • Kidney stones or history of renal colic 10. Medications:
  • Steroids use (past or present)
  • Anti rejection drugs in the last 5 years
  • Anticonvulsant (carbamezapine, hydantoin, Phenobarbital etc) in the last 5 years
  • Any anti osteoporotic medication: Prolia, Bisphosphonates, Teriperatide, Evista, Protelos, (past or present)
  • Post menopausal HRT (in the last 10 years)
  • Aromatase inhibitors: Femara, Arimadex (past or present)
  • +2 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Soroka University Medical Center

Beersheba, Israel

Location

MeSH Terms

Conditions

Vitamin D Deficiency

Interventions

Vitamin D

Condition Hierarchy (Ancestors)

AvitaminosisDeficiency DiseasesMalnutritionNutrition DisordersNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

SecosteroidsSteroidsFused-Ring CompoundsPolycyclic Compounds

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Endocrinologist

Study Record Dates

First Submitted

September 24, 2012

First Posted

September 27, 2012

Study Start

October 1, 2012

Primary Completion

October 1, 2018

Study Completion

December 1, 2018

Last Updated

April 5, 2019

Record last verified: 2019-04

Data Sharing

IPD Sharing
Will not share

Locations